Stock COOL CORE ONE LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Core One Labs Inc.

Equities

COOL

CA21872J3073

Pharmaceuticals

Delayed Canadian Securities Exchange
Other stock markets
 13:43:46 2024-04-26 EDT 		5-day change 1st Jan Change
0.19 CAD 0.00% Intraday chart for Core One Labs Inc. -19.15% -34.48%
04-09 Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding CI
02-29 Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: März 2018 2019 2020 2021 2023
Capitalization 1 76.95 44.3 5.081 110.5 18.35
Enterprise Value (EV) 1 76.68 48.26 3.611 109.7 17.89
P/E ratio -6.37 x -2.33 x -0.3 x -3.21 x -0.84 x
Yield - - - - -
Capitalization / Revenue 18.9 x 8.79 x - 256 x 40 x
EV / Revenue 18.8 x 9.57 x - 254 x 39 x
EV / EBITDA -6.79 x -3.94 x -0.77 x -8.98 x -2.32 x
EV / FCF -6.51 x -54.9 x -0.62 x 146 x -
FCF Yield -15.4% -1.82% -161% 0.68% -
Price to Book 4.71 x 8.21 x 6.67 x 41 x 2.73 x
Nbr of stocks (in thousands) 1,145 1,247 1,672 13,415 44,747
Reference price 2 67.20 35.52 3.040 8.240 0.4100
Announcement Date 19-05-06 20-08-18 21-06-28 22-06-29 23-08-03
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2023
Net sales 1 4.081 5.042 - 0.4316 0.4585
EBITDA 1 -11.29 -12.25 -4.702 -12.21 -7.721
EBIT 1 -11.65 -17.65 -6.599 -12.25 -7.763
Operating Margin -285.57% -350.11% - -2,837.74% -1,693.05%
Earnings before Tax (EBT) 1 -13.15 -21.65 -46.9 -37.05 -15.98
Net income 1 -12.29 -21.46 -54.62 -37.05 -15.98
Net margin -301.09% -425.72% - -8,585.16% -3,485.36%
EPS 2 -10.56 -15.25 -10.27 -2.570 -0.4886
Free Cash Flow 1 -11.77 -0.8787 -5.827 0.7502 -
FCF margin -288.5% -17.43% - 173.82% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 19-05-06 20-08-18 21-06-28 22-06-29 23-08-03
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2023
Net Debt 1 - 3.96 - - -
Net Cash position 1 0.27 - 1.47 0.84 0.46
Leverage (Debt/EBITDA) - -0.323 x - - -
Free Cash Flow 1 -11.8 -0.88 -5.83 0.75 -
ROE (net income / shareholders' equity) -96.8% -198% -852% -764% -
ROA (Net income/ Total Assets) -42.6% -56.8% -30.2% -89.4% -
Assets 1 28.84 37.81 180.9 41.47 -
Book Value Per Share 2 14.30 4.330 0.4600 0.2000 0.1500
Cash Flow per Share 2 0.3600 0.0700 0.0400 0.0400 0.0100
Capex 1 5.11 1.64 - 0.01 0.03
Capex / Sales 125.25% 32.43% - 2.01% 5.87%
Announcement Date 19-05-06 20-08-18 21-06-28 22-06-29 23-08-03
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Alternative Medicine

1st Jan change Capi.
CORE ONE LABS INC. Stock Core One Labs Inc.
-34.48% 6.54M
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+35.04% 5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.13% 4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.46% 3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+0.51% 3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-3.53% 2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+41.15% 1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-5.15% 1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+0.09% 1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-12.97% 1.53B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. COOL Stock
  4. Financials Core One Labs Inc.